Indaptus doses first patient in Phase 1b.2 study of Decoy20 withTislelizumab

Indaptus Therapeutics (INDP) announces that the first patient has been dosed in the expansion arm of its Phase 1b/2 clinical trial evaluating Decoy20 in combination with BeOne’s PD-1 checkpoint inhibitor, tislelizumab. This newly activated arm of the trial will assess safety, dose optimization, and early signs of anti-tumor activity in patients with advanced solid tumors, previously treated with a checkpoint inhibitor or with tumors typically unresponsive to a checkpoint inhibitor. Over 25 patients have now received weekly doses of Decoy20 at 30 million cells and the treatment has been well tolerated. Most side effects were mild or moderate and were transient. Patients enrolled in the Decoy20 + tislelizumab combination arm will either have tumors that did not respond – or stopped responding – to prior checkpoint inhibitor therapy, or have tumor types that are typically unresponsive. This will allow the Company to determine that any observed benefit is likely due to the combination approach. Initially, patients will be enrolled sequentially onto combination treatment to closely monitor safety before expanding enrollment.